DEC 2 8 2001 THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Application of)
d. Paul REDMOND et al.	,)
Application No. 09/971,774) Examiner: Unassigned
Filed: October 9, 2001)) Group Art Unit: 1623

For: USE OF TAUROLIDINE AND/OR TAURULTAM FOR TREATMENT OF ABDOMINAL CANCER AND/OR FOR PREVENTION OF METASTASES

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The material listed on the accompanying Form PTO-1449 and Forms PTO-892, from the parent application having U.S. Serial Number 09/493,797, is cited in compliance with the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Applicants respectfully request that the Examiner consider these references with respect to the present application. Copies of these references can be found with the parent application and, accordingly, will not be resubmitted unless requested by the Examiner.

Reference AG is a newly cited reference and Applicants respectfully request the Examiner also consider this reference with respect to the present application.

Respectfully submitted,

Ву

George R. Repper Attorney for Applicants Registration No. 31,414 ROTHWELL FIGG FRN

ROTHWELL, FIGG, ERNST & MANBECK, P.C.

Suite 701-E, 555 13th Street, N.W.

Washington, D.C. 20004 Telephone: (202) 783-6040

1:\DATA\Clients\1194\1194-180.IDS